Search Results
Showing Results for infusion therapies
Prof. Joaquim Ferreira shares insights from EAN 2025 on the future of Parkinson’s disease care. He discusses realistic timelines for DMTs, the evolving role of gene therapy for genetic subgroups, and the potential of adaptive deep brain stimulation. Prof. Ferreira also highlights the growing importance of optimizing current treatments, interdisciplinary care, and addressing persistent challenges such as gait disturbance, dyskinesia, and cognitive decline.
At EAN 2025, Prof. K. Ray Chaudhuri shares insights into cutting-edge Parkinson's drug delivery methods, the future of biomarker-driven care, advances in managing sleep disturbances, and the vital role of lifestyle modifications in optimizing patient outcomes.
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder of upper and lower motor neurons that results in progressive motor impairment. ALS is the most common disease of motor neurons with an annual incidence of approximately 1.7–2.5 per 100,000 people. It is a ...
In this Q&A, Dr Andy Liu, Associate Professor of Neurology at Duke University School of Medicine, discusses his presentation on the clinical use of lecanemab in Alzheimer’s disease. Drawing on real-world experience and findings from the 2022 CLARITY AD study, Dr Liu explores the treatment’s benefits, challenges in daily practice and the importance of patient-centred care in this evolving therapeutic landscape.
Seizures are one of the most frequent neurological disorders in neonates − the incidence of seizures in infants born at term is 1–3 per 1,000 live births, and is even higher in both preterm and very-low-birth-weight infants at 1–13 per 1,000 live births.1 Seizures may ...
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a rare, autoimmune neurological disorder in which peripheral nerve demyelination typically results in weakness, impaired limb sensation, fatigue and pain.1–4 CIDP may adversely affect activities of daily living, with a substantial impact on functional ...
The phase 3b SMART study has shown that 83% of paediatric patients with spinal muscular atrophy (SMA) weighing between 8.5 and 21 kg achieved significant motor improvements following treatment with intravenous onasemnogene abeparvovec in a recent article published in Neurology.
Explore ground-breaking advancements in the treatment of movement disorders in this insightful interview with Prof. K. Ray Chaudhuri, who shares his key takeaways from the 10th Congress of the European Academy of Neurology meeting in Helsinki. He discusses promising new therapies, personalized care approaches, and significant research on the staging of Parkinson's. Additionally, Prof. Chaudhuri emphasizes the importance of holistic treatment, stepped-care strategies, remote management, and the potential of wearable technology in improving patient outcomes, bringing his wealth of knowledge and insights to touchNEUROLOGY
Welcome to the latest edition of touchREVIEWS in Neurology. We are excited to present a collection of articles that showcase the latest advancements and diverse perspectives in neurological research and treatment. This issue features insightful reviews and editorials from esteemed ...
Neuromyelitis optica spectrum disorders (NMOSD) are a group of relapsing autoimmune diseases of the central nervous system. The clinical hallmarks of NMOSD are myelitis and optic neuritis; however, a wider clinical spectrum has been recognized.1Â The majority of patients with ...
Affecting over 70 million patients worldwide, epilepsy is a chronic neurological disorder characterized by intermittent bursts of hyper-synchronous neuronal discharges.1Â The manifestations are variable but reflective of the unique milieu and biology of epileptogenic foci.2Â Pharmacological treatment with antiepileptic drugs (AEDs) ...
Neuromyelitis optica spectrum disorder (NMOSD) is a rare inflammatory autoimmune disease of the central nervous system (CNS) with a worldwide distribution.1Â The first clinical description of NMOSD was made a century ago by Devic and Gault, who documented patients with ...
Parkinson’s disease (PD) is a chronic progressive neurodegenerative disorder characterized by the degeneration of nigrostriatal dopaminergic neurons, with its incidence increasing globally.1 With disease progression, the benefit from medications shortens, and symptom control becomes strictly dependent on peripheral levodopa (...
Despite being one of the most common serious psychiatric disorders, major depression remains difficult to treat with only 30-50% of patients achieving remission from monotherapy or talk therapy, however many promising new antidepressants are currently under investigation. We were delighted ...
Over the past two decades, monoclonal antibodies targeting the surface antigen CD20 have emerged as highly effective disease-modifying therapies (DMTs) for multiple sclerosis (MS).1Â The major mechanism of action of these therapies is via B-cell depletion, as CD20 is expressed ...
Multiple sclerosis (MS) is an immune-mediated neurodegenerative disease affecting approximately 2.5 million individuals worldwide.1,2Â Pathologically, MS is mostly characterized by inflammation, demyelination, axonal degeneration and gliosis. Clinically, a wide range of symptoms can occur, including cognitive, motor and sensory impairments.3 The ...
Myasthenia gravis (MG) represents the major and most frequent primary disorder of the neuromuscular junction. Clinical hallmarks are variable and include exercise-induced weakness involving extraocular, bulbar, limb and/or axial muscles.1Â Respiratory involvement, characterized by orthopnoea or dyspnoea with exertion, ...
Paediatric-onset multiple sclerosis (POMS) is the symptom onset and diagnosis of multiple sclerosis (MS) before the age of 18.1Â Diagnostic criteria were revised by the International Pediatric MS Study Group in 2013. Compared to patients with adult-onset MS (AOMS), young patients are ...
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Sign up with an Email
Or use a .
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
